February 25, 2026 – Garching / Munich, Germany
ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotechnology company, has announced that new exploratory and post-hoc subgroup analysis data from its Phase 3 COMPETE trial will be presented at the 23rd Annual European Neuroendocrine Tumor Society (ENETS 2026) Conference in Kraków, Poland. The presentation will spotlight clinical findings in pancreatic neuroendocrine tumors (pNETs), reinforcing the therapeutic potential of ITM’s investigational radiopharmaceutical candidate 177Lu-edotreotide (ITM-11). The company will also host an expert-led satellite symposium and scientific exhibition booth, strengthening engagement with the global nuclear medicine and oncology research community.
Post-Hoc Analysis Strengthens Clinical Evidence
The oral presentation will focus on subgroup outcomes from the COMPETE study evaluating 177Lu-edotreotide, a targeted radiotherapeutic agent designed to deliver precision radiation directly to tumor cells expressing somatostatin receptors. The Phase 3 trial compared the investigational therapy against everolimus, a standard targeted molecular treatment, in patients with inoperable, progressive Grade 1 and Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
The study successfully met its primary endpoint, demonstrating statistically significant improvement in progression-free survival (PFS) for patients treated with 177Lu-edotreotide. The newly announced subgroup analysis is expected to provide deeper insight into therapeutic benefit among pancreatic NET populations, an area of high unmet clinical need due to limited treatment options and complex tumor biology.
By expanding the evidence base through post-hoc evaluation, ITM aims to further characterize response variability, optimize patient selection strategies, and support future regulatory and clinical development pathways.
Advertisement
Advancing Radiopharmaceutical Oncology Innovation
Radiopharmaceutical therapies represent a rapidly advancing frontier in precision oncology, combining diagnostic imaging and targeted radiation delivery to treat malignant tumors with high specificity. ITM’s investigational platform integrates proprietary medical radioisotopes with tumor-targeting molecules to enhance therapeutic efficacy while minimizing systemic toxicity.
177Lu-edotreotide is engineered to bind somatostatin receptors overexpressed on neuroendocrine tumor cells, enabling localized radiation exposure. This targeted mechanism positions the therapy as a next-generation alternative to conventional systemic treatments, particularly in progressive or metastatic disease settings.
In addition to COMPETE, the agent is also being evaluated in the ongoing COMPOSE Phase 3 study, which includes patients with aggressive Grade 2 and Grade 3 somatostatin receptor–positive GEP-NETs. The broader clinical program underscores ITM’s commitment to expanding radiopharmaceutical treatment options across multiple neuroendocrine tumor subtypes.
Scientific Collaboration at ENETS 2026
To complement the data presentation, ITM will host an interactive satellite symposium titled Radiopharmaceutical Therapy in NETs, convening international oncology and nuclear medicine experts to discuss emerging treatment paradigms, clinical challenges, and evolving therapeutic algorithms.
The symposium will feature multidisciplinary perspectives spanning medical oncology, nuclear medicine, and translational research, reflecting the collaborative framework required to advance radiopharmaceutical adoption in clinical practice. Topics will include patient selection optimization, combination treatment strategies, and integration of targeted radionuclide therapy into standard oncology care pathways.
ITM’s presence at ENETS 2026 highlights the growing global momentum surrounding radioligand therapy development, as clinical evidence continues to validate the role of targeted radioisotopes in improving outcomes for patients with rare and difficult-to-treat cancers.
With regulatory review processes anticipated in future development stages, expanded subgroup analyses and scientific dialogue will play a critical role in supporting market authorization strategies and clinical guideline inclusion.
Source: ITM Isotope Technologies Munich press release
